ArticleBlood cell therapy2026
Return to Work After Hematopoietic Stem Cell Transplantation: A Longitudinal Analysis of Fatigue and Organ-Specific Chronic Graft-versus-Host Disease.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Return to work (RTW) indicates long-term functional recovery following hematopoietic stem cell transplantation (HSCT), yet the impact of organ-specific chronic graft-versus-host disease (cGvHD) remains understudied. Objective: To determine the probability and timing of RTW and identify its predictors, specifically fatigue and organ-specific cGvHD, using longitudinal nursing data. Methods: This retrospective cohort study analyzed 2,334 longitudinal nursing assessment records from 80 HSCT recipients (2016-2021). The probability of RTW over time was estimated using the Kaplan-Meier method. Time-dependent Cox regression models were used to identify predictors while adjusting for age, sex, and clinical confounders. Results: The median follow-up was 507 days (interquartile range [IQR] 224-797). The median time to RTW was 312.5 days (IQR 144.0-567.2). The Kaplan-Meier-estimated probability of RTW was 17.8%, 34.1%, and 53.3% at 6, 12, and 24 months, respectively. Multivariable analysis revealed that allogeneic HSCT (hazard ratio [HR]=0.17, Conclusions: RTW after HSCT is a delayed and symptom-driven recovery process. Fatigue was a universal barrier across transplant types, while allogeneic recipients faced additional obstacles from organ-specific cGvHD. Systematic assessment and targeted rehabilitation for fatigue and musculoskeletal manifestations are essential to support vocational reintegration. Although pulmonary involvement did not reach statistical significance, it showed a trend toward delayed RTW and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.